| Gender | |
| male | 39 (55.71) |
| female | 31 (44.29) |
| Age (years) | 5 (3 months–12 years) |
| ≤1 | 18 (25.71) |
| >1–5 | 21 (30.00) |
| >5–12 | 31 (44.29) |
| Diagnosis | |
| ALL | 23 (32.86) |
| AML | 22 (31.43) |
| relapsed ALL | 5 (7.14) |
| aplastic anaemia | 2 (2.86) |
| CGD | 2 (2.86) |
| MDS + JMML | 2 (2.86) |
| JMML | 2 (2.86) |
| CML | 2 (2.86) |
| othera | 10 (14.29) |
| Bone marrow transplant recipient | |
| no | 51 (72.86) |
| yes | 19 (27.14) |
| Type of bone marrow transplant | |
| matched sibling | 4 (21.05) |
| unrelated peripheral blood stem cell | 4 (21.05) |
| haploidentical | 4 (21.05) |
| unrelated cord blood | 3 (15.79) |
| matched unrelated donor | 3 (15.79) |
| cord blood | 1 (5.26) |
| Covariates associated with reduced absorption | |
| concurrent PPIb | 14 (20.00) |
| concurrent ranitidine | 2 (2.86) |
| concurrent metoclopramide | 18 (25.71) |
| mucositis | 6 (8.57) |
| enteral feeding | 16 (22.86) |
| At least one covariate | 38 (54.29) |
| Gender | |
| male | 39 (55.71) |
| female | 31 (44.29) |
| Age (years) | 5 (3 months–12 years) |
| ≤1 | 18 (25.71) |
| >1–5 | 21 (30.00) |
| >5–12 | 31 (44.29) |
| Diagnosis | |
| ALL | 23 (32.86) |
| AML | 22 (31.43) |
| relapsed ALL | 5 (7.14) |
| aplastic anaemia | 2 (2.86) |
| CGD | 2 (2.86) |
| MDS + JMML | 2 (2.86) |
| JMML | 2 (2.86) |
| CML | 2 (2.86) |
| othera | 10 (14.29) |
| Bone marrow transplant recipient | |
| no | 51 (72.86) |
| yes | 19 (27.14) |
| Type of bone marrow transplant | |
| matched sibling | 4 (21.05) |
| unrelated peripheral blood stem cell | 4 (21.05) |
| haploidentical | 4 (21.05) |
| unrelated cord blood | 3 (15.79) |
| matched unrelated donor | 3 (15.79) |
| cord blood | 1 (5.26) |
| Covariates associated with reduced absorption | |
| concurrent PPIb | 14 (20.00) |
| concurrent ranitidine | 2 (2.86) |
| concurrent metoclopramide | 18 (25.71) |
| mucositis | 6 (8.57) |
| enteral feeding | 16 (22.86) |
| At least one covariate | 38 (54.29) |
Values are n (%) or median (range).
CGD, chronic granulomatous disease; MDS, myelodysplastic syndrome; JMML, juvenile myelomonocytic leukaemia.
Wiskott–Aldrich syndrome, Omenn’s syndrome, anaplastic large cell lymphoma, congenital neutropenia, severe combined immunodeficiency, haemophagocytic lymphohistiocytosis, Hurler’s syndrome, IL-10 receptor-deficient inflammatory bowel disease, Langerhans cell histiocytosis and X-linked adrenoleucodystrophy, each of which were n=1 (1.43%).
Omeprazole or esomeprazole
| Gender | |
| male | 39 (55.71) |
| female | 31 (44.29) |
| Age (years) | 5 (3 months–12 years) |
| ≤1 | 18 (25.71) |
| >1–5 | 21 (30.00) |
| >5–12 | 31 (44.29) |
| Diagnosis | |
| ALL | 23 (32.86) |
| AML | 22 (31.43) |
| relapsed ALL | 5 (7.14) |
| aplastic anaemia | 2 (2.86) |
| CGD | 2 (2.86) |
| MDS + JMML | 2 (2.86) |
| JMML | 2 (2.86) |
| CML | 2 (2.86) |
| othera | 10 (14.29) |
| Bone marrow transplant recipient | |
| no | 51 (72.86) |
| yes | 19 (27.14) |
| Type of bone marrow transplant | |
| matched sibling | 4 (21.05) |
| unrelated peripheral blood stem cell | 4 (21.05) |
| haploidentical | 4 (21.05) |
| unrelated cord blood | 3 (15.79) |
| matched unrelated donor | 3 (15.79) |
| cord blood | 1 (5.26) |
| Covariates associated with reduced absorption | |
| concurrent PPIb | 14 (20.00) |
| concurrent ranitidine | 2 (2.86) |
| concurrent metoclopramide | 18 (25.71) |
| mucositis | 6 (8.57) |
| enteral feeding | 16 (22.86) |
| At least one covariate | 38 (54.29) |
| Gender | |
| male | 39 (55.71) |
| female | 31 (44.29) |
| Age (years) | 5 (3 months–12 years) |
| ≤1 | 18 (25.71) |
| >1–5 | 21 (30.00) |
| >5–12 | 31 (44.29) |
| Diagnosis | |
| ALL | 23 (32.86) |
| AML | 22 (31.43) |
| relapsed ALL | 5 (7.14) |
| aplastic anaemia | 2 (2.86) |
| CGD | 2 (2.86) |
| MDS + JMML | 2 (2.86) |
| JMML | 2 (2.86) |
| CML | 2 (2.86) |
| othera | 10 (14.29) |
| Bone marrow transplant recipient | |
| no | 51 (72.86) |
| yes | 19 (27.14) |
| Type of bone marrow transplant | |
| matched sibling | 4 (21.05) |
| unrelated peripheral blood stem cell | 4 (21.05) |
| haploidentical | 4 (21.05) |
| unrelated cord blood | 3 (15.79) |
| matched unrelated donor | 3 (15.79) |
| cord blood | 1 (5.26) |
| Covariates associated with reduced absorption | |
| concurrent PPIb | 14 (20.00) |
| concurrent ranitidine | 2 (2.86) |
| concurrent metoclopramide | 18 (25.71) |
| mucositis | 6 (8.57) |
| enteral feeding | 16 (22.86) |
| At least one covariate | 38 (54.29) |
Values are n (%) or median (range).
CGD, chronic granulomatous disease; MDS, myelodysplastic syndrome; JMML, juvenile myelomonocytic leukaemia.
Wiskott–Aldrich syndrome, Omenn’s syndrome, anaplastic large cell lymphoma, congenital neutropenia, severe combined immunodeficiency, haemophagocytic lymphohistiocytosis, Hurler’s syndrome, IL-10 receptor-deficient inflammatory bowel disease, Langerhans cell histiocytosis and X-linked adrenoleucodystrophy, each of which were n=1 (1.43%).
Omeprazole or esomeprazole
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
